Targeted Cancer Therapy for Patients With 17p Deletion

Time: 2:00 pm
day: Day One


  • Discussing Del(17p) as a potential platform-wide predictive biomarker for amanitin based ADCs
  • Highlighting superior efficacy of amanitin based ADCs in cancer models with 17p loss
  • Outlining the expedited clinical development of HDP-101 for Del(17p) patients